For Industry & VCs

CD3 advances early-stage academic discoveries into characterized lead and preclinical drug candidates, ready for (pre-)clinical development. Once a programme reaches sufficient maturity, assets can be licensed to a pharma or biotech company to progress into clinical development.

Our out‑licensing pipeline includes lead and preclinical‑stage candidates spanning multiple therapeutic areas. To date, CD3 has successfully completed more than 20 commercial deals with pharma partners.

Interested in our available assets?

CD3 invests in and actively supports the creation of new biotech ventures. These companies may originate from CD3’s own portfolio or from opportunities sourced through external academic institutions and technology transfer offices. In each case, CD3 provides capital, initial company setup and operational support, and the hands‑on engagement required to build robust, performing biotech companies.

For founders and researchers, this empowers them to build and grow a company around their innovation, while staying closely supported through key development stages.

An example of such a venture creation is Rewind Therapeutics.

Considering a spin-off from your research programme?

CD3 invests directly in biotech companies with promising therapeutic programmes, complementing our spin-off activities.  In addition to capital, companies benefit from direct access to CD3’s drug discovery and development expertise, infrastructure, and network. This allows for hands‑on scientific and strategic support throughout development, from target validation and discovery strategy through to positioning for downstream development and partnering.

For biotech teams, this means working with a partner committed to long-term engagement and shared risk, focused on advancing high-potential science into meaningful development opportunities.

Looking for an investor with deep drug discovery expertise?